Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Clyra Medical Technology Inc [Member] Common Stock [Member]	Clyra Medical Technology Inc [Member] Additional Paid-in Capital [Member]	Clyra Medical Technology Inc [Member] Retained Earnings [Member]	Clyra Medical Technology Inc [Member] AOCI Attributable to Parent [Member]	Clyra Medical Technology Inc [Member] Noncontrolling Interest [Member]	Clyra Medical Technology Inc [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2020							225,885,682
Balance at Dec. 31, 2020							$ 151,000	$ 135,849,000	$ (132,041,000)	$ (101,000)	$ (4,093,000)	$ (235,000)
Sale of common stock for cash (in shares)							13,330,619
Sale of common stock for cash							$ 9,000	2,097,000	0	0	0	2,106,000
Issuance of common stock for service (in shares)							747,487
Issuance of common stock for service							$ 1,000	110,000	0	0	0	111,000
Stock option compensation expense	$ 0	$ 161,000	$ 0	$ 0	$ 0	$ 161,000	0	424,000	0	0	0	424,000
Noncontrolling interest allocation							0	(313,000)	0	0	313,000	0
Foreign currency translation							0	0	0	(2,000)	0	(2,000)
Net loss							0	0	(1,631,000)	0	(247,000)	(1,878,000)
Foreign currency translation							0	0	0	(2,000)	0	(2,000)
Warrants and conversion feature issued as discount on convertible note payable							$ 0	35,000	0	0	0	35,000
Clyra Medical securities offering	0	0	0	0	50,000	50,000
Balance (in shares) at Mar. 31, 2021							239,963,788
Balance at Mar. 31, 2021							$ 161,000	138,363,000	(133,672,000)	(103,000)	(3,977,000)	772,000
Balance (in shares) at Dec. 31, 2020							225,885,682
Balance at Dec. 31, 2020							$ 151,000	135,849,000	(132,041,000)	(101,000)	(4,093,000)	(235,000)
Foreign currency translation												(2,000)
Net loss												(3,668,000)
Foreign currency translation												(2,000)
Balance (in shares) at Jun. 30, 2021							250,996,373
Balance at Jun. 30, 2021							$ 168,000	140,292,000	(135,294,000)	(103,000)	(3,831,000)	1,232,000
Balance (in shares) at Dec. 31, 2020							225,885,682
Balance at Dec. 31, 2020							$ 151,000	135,849,000	(132,041,000)	(101,000)	(4,093,000)	(235,000)
Balance (in shares) at Dec. 31, 2021							255,893,726
Balance at Dec. 31, 2021							$ 171,000	143,718,000	(139,121,000)	(115,000)	(3,720,000)	933,000
Balance (in shares) at Mar. 31, 2021							239,963,788
Balance at Mar. 31, 2021							$ 161,000	138,363,000	(133,672,000)	(103,000)	(3,977,000)	772,000
Sale of common stock for cash (in shares)							8,627,237
Sale of common stock for cash							$ 6,000	1,408,000	0	0	0	1,414,000
Issuance of common stock for service (in shares)							357,132
Issuance of common stock for service							$ 0	60,000	0	0	0	60,000
Stock option compensation expense	0	102,000	0	0	0	102,000	0	330,000	0	0	0	330,000
Noncontrolling interest allocation							0	(314,000)	0	0	314,000	0
Foreign currency translation							0	0	0	0	0	0
Net loss							0	0	(1,622,000)	0	(168,000)	(1,790,000)
Foreign currency translation							$ 0	0	0	0	0	0
Conversion of notes (in shares)							1,966,439
Conversion of notes							$ 1,000	327,000	0	0	0	328,000
Issuance of common stock for interest (in shares)							81,777
Issuance of common stock for interest							$ 0	16,000	0	0	0	16,000
Balance (in shares) at Jun. 30, 2021							250,996,373
Balance at Jun. 30, 2021							$ 168,000	140,292,000	(135,294,000)	(103,000)	(3,831,000)	1,232,000
Balance (in shares) at Dec. 31, 2021							255,893,726
Balance at Dec. 31, 2021							$ 171,000	143,718,000	(139,121,000)	(115,000)	(3,720,000)	933,000
Sale of common stock for cash (in shares)							6,703,789
Sale of common stock for cash							$ 4,000	1,198,000	0	0	0	1,202,000
Issuance of common stock for service (in shares)							86,752
Issuance of common stock for service							$ 0	17,000	0	0	0	17,000
Stock option compensation expense	0	141,000	0	0	0	141,000	0	660,000	0	0	0	660,000
Noncontrolling interest allocation							0	(528,000)	0	0	528,000	0
Foreign currency translation							0	0	0	(8,000)	0	(8,000)
Foreign currency translation							$ 0	0	0	(8,000)	0	(8,000)
Balance (in shares) at Mar. 31, 2022							262,684,267
Balance at Mar. 31, 2022							$ 175,000	145,206,000	(140,773,000)	(123,000)	(3,084,000)	1,401,000
Balance (in shares) at Dec. 31, 2021							255,893,726
Balance at Dec. 31, 2021							$ 171,000	143,718,000	(139,121,000)	(115,000)	(3,720,000)	933,000
Foreign currency translation												(11,000)
Net loss												(2,877,000)
Foreign currency translation												(11,000)
Balance (in shares) at Jun. 30, 2022							268,036,728
Balance at Jun. 30, 2022							$ 179,000	146,422,000	(142,001,000)	(126,000)	(3,086,000)	1,388,000
Balance (in shares) at Mar. 31, 2022							262,684,267
Balance at Mar. 31, 2022							$ 175,000	145,206,000	(140,773,000)	(123,000)	(3,084,000)	1,401,000
Sale of common stock for cash (in shares)							5,011,570
Sale of common stock for cash							$ 4,000	944,000	0	0	0	948,000
Issuance of common stock for service (in shares)							340,891
Issuance of common stock for service							$ 0	59,000	0	0	0	59,000
Stock option compensation expense	$ 0	$ 82,000	$ 0	$ 0	$ 0	$ 82,000	0	234,000	0	0	0	234,000
Noncontrolling interest allocation							0	(103,000)	0	0	103,000	0
Foreign currency translation							0	0	0	(3,000)	0	(3,000)
Net loss							0	0	(1,228,000)	0	(105,000)	(1,333,000)
Foreign currency translation							$ 0	0	0	(3,000)	0	(3,000)
Balance (in shares) at Jun. 30, 2022							268,036,728
Balance at Jun. 30, 2022							$ 179,000	$ 146,422,000	$ (142,001,000)	$ (126,000)	$ (3,086,000)	$ 1,388,000